J.P. MORGAN INITIATES $HIMS PRICE TARGET: $35 RATING: OVERWEIGHT "We think the recent Novo partnership could mark a turning point, removing a significant legal overhang and positioning HIMS as a platform that offers branded, generic, and compounded products" "HIMS recently announced that it’s on track for 100k+ monthly Wegovy prescriptions. We estimate this implies a ~$350–400M annual revenue run-rate and compares to ~250k GLP-1 subscribers pre-Novo." "We think HIMS’ weight loss specialty can still grow this year, and we expect branded and compounded contribution dollars to be similar." "Peptide legalization expands TAM… Consumer interest in peptides has surged in recent years, and we believe HIMS is well positioned to be an early mover given its ownership of US peptide manufacturing and compounding facilities." "We believe peptides, which pharma cannot patent, have the potential to be a meaningful new specialty and source of upside to our model in 2027+." h/t @DustinHuntwn

@himshouse 35 maybe by end of May. Triple digits in the next 12-24 months 👀 $HIMS

@arthritisfinger @himshouse 35 would be easily achieved in this week